<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417349</url>
  </required_header>
  <id_info>
    <org_study_id>SESAME</org_study_id>
    <nct_id>NCT03417349</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of SOFIA™/SOFIA™ PLUS for Direct Aspiration in Acute Ischemic Stroke</brief_title>
  <acronym>SESAME</acronym>
  <official_title>Safety and Effectiveness of SOFIA™/SOFIA™ PLUS When Used for Direct Aspiration as a First Line Treatment Technique in Patients Suffering an Acute Ischemic Stroke in the Anterior Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Markus Alfred Möhlenbruch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Microvention-Terumo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eppdata Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sesame is a European, multi-center, single arm, prospective, observational registry.

      Sesame aims to demonstrate that use of SOFIA™/SOFIA™ PLUS catheter for direct aspiration as a
      first line treatment technique is fast, safe and effective in patients suffering an Acute
      Ischemic Stroke when assessed at 24 hours, discharge and 90 days after treatment. 250
      patients will be enrolled. All patients will be followed for 90 days or until death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several publications describing the use of aspiration as a first line treatment technique in
      AIS patients have shown superior technical results with similar clinical outcomes to those
      seen when using a traditional stent retriever. They have also shown decreased procedure time
      and cost. The aim of this study is to show similar results in terms of speed, Effectiveness
      and safety when SOFIA™/ SOFIA™ PLUS is the catheter used for first line aspiration
      thrombectomy.

      The SOFIA™ (Soft Torqueable Catheter Optimized For Intracranial Access) and SOFIA™ PLUS
      Catheter are single lumen, flexible catheters, designed with coil and braid reinforcement.
      The SOFIA™ / SOFIA™ PLUS catheters have a soft distal tip for easy navigation in tortuous
      vessels. The tip is steam shapable and the proximal shaft torquable to help steer around
      challenging bifurcations. The coil and braid construction provides enhanced kink resistance
      and 1:1 push / pull control. Once navigated to the site of the occlusion, the SOFIA™ / SOFIA™
      PLUS catheters can be used in conjunction with an aspiration source, such as a pump or
      syringe, to facilitate aspiration thrombectomy of the occluded vessel. The SOFIA™ / SOFIA™
      PLUS catheters have large lumens, developed to maximize aspiration power and capture of
      thrombus.

      SESAME is a multi-center, single arm, prospective, observational registry of the SOFIA™/
      SOFIA™ PLUS Catheter in Europe. Consecutive patients presenting within 6 hours of symptom
      onset with an anterior circulation large vessel occlusion (LVO) acute ischemic stroke (within
      the internal carotid artery and internal carotid terminus, middle cerebral -M1/M2 segments)
      will be treated using aspiration thrombectomy as first intention and site routine practice.
      Devices received CE-mark and will be used according to the 'Instructions For Use'.

      The follow-up visits will occur at 24 +/- 12 hours, at patient discharge, and 90+/-14 days
      post-procedure.

      Furthermore the study design is adaptive, prospectively stating interim analyses with
      specified stopping rules, which allow for the possibility of the study to terminate early
      based on either a determination of study success or of the futility to continue further
      enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Dichotomization of patients into good functional outcome defined as a modified Rankin Score (mRS) ≤ 2 and bad functional outcome defined as mRS &gt;2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - neurological</measure>
    <time_frame>Prior to discharge / approximated 3-7 days</time_frame>
    <description>Occurrence of major neurological events (stroke, intracranial hemorrhage, intracerebral hemorrhage, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - procedural</measure>
    <time_frame>90 days</time_frame>
    <description>Devices and procedure related adverse events within 90 days of follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ENT</measure>
    <time_frame>Intra-procedure</time_frame>
    <description>Infarct in a New Territory After Treatment Administration as seen on final control angiogram at the end of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sICH</measure>
    <time_frame>24 hours</time_frame>
    <description>Occurrence of symptomatic intracranial hemorrhage (sICH) within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel damage</measure>
    <time_frame>Intra-procedure</time_frame>
    <description>Occurrence of intracranial vessel damage at the end of the procedure as seen on final control angiogram at the end of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recanalization - Aspiration</measure>
    <time_frame>Intra-procedure</time_frame>
    <description>Proportion of patients having complete recanalization (TICI≥ 2b) just after first line aspiration treatment as seen on control angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recanalization - Other</measure>
    <time_frame>Intra-procedure</time_frame>
    <description>Proportion of patients having complete recanalization (TICI ≥ 2b) af-ter thrombectomy using an additional devices as seen on control angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recanalization- Aspiration</measure>
    <time_frame>Intra-procedure</time_frame>
    <description>Time from groin puncture to complete recanalization (TICI ≥ 2b) in patients after first line aspiration treatment as seen on control angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recanalization- Other</measure>
    <time_frame>Intra-procedure</time_frame>
    <description>Time from groin puncture to complete recanalization (TICI ≥ 2b) in patients after thrombectomy using an additional device as seen on control angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to angio</measure>
    <time_frame>Intra-procedure</time_frame>
    <description>Time from CT-scan/MRI at the institution to groin access</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom onset</measure>
    <time_frame>Pre-procedure</time_frame>
    <description>Time from symptom onset to CT-scan/MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological outcome 24</measure>
    <time_frame>24 hours</time_frame>
    <description>National Institutes of Health Stroke Scale (NIHSS) score at 24 hours, total and subscale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological outcome discharge</measure>
    <time_frame>Discharge / approximately 3-7 days</time_frame>
    <description>National Institutes of Health Stroke Scale (NIHSS) score at discharge, total and subscale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological outcome 90 days</measure>
    <time_frame>90 days / +/- 14 days</time_frame>
    <description>National Institutes of Health Stroke Scale (NIHSS) score at 90 days, total and subscale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of disability - discharge</measure>
    <time_frame>Discharge/ approximately 3-7 days</time_frame>
    <description>modified Rankin Score at discharge, total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of disability - 90d</measure>
    <time_frame>90 days / +/- 14 days</time_frame>
    <description>modified Rankin Score at 90 day follow-up, total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life at 90 days</measure>
    <time_frame>90 days / +/- 14 days</time_frame>
    <description>Quality of Life at 90 days assessed via PROMIS Scale v1.2 - Global Health, total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging</measure>
    <time_frame>24 hours</time_frame>
    <description>Difference of Alberta stroke program early CT score (ASPECTs) scores in CT/MRI pretreatment vs. 24h, total scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging - perfusion</measure>
    <time_frame>24 hours</time_frame>
    <description>In the subgroup of patients with additional perfusion CT (as per local standard of care): volume of saved brain tissue determined by predictive modeling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economics -device</measure>
    <time_frame>Intra-procedure</time_frame>
    <description>Device costs (standardized cost of all devices as well as human resources and medication used during index procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economics - hospital</measure>
    <time_frame>Discharge / approximately 3-7 days</time_frame>
    <description>Hospital length of stay</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cerebrovascular Stroke</condition>
  <condition>Stroke, Acute</condition>
  <condition>Cerebral Stroke</condition>
  <arm_group>
    <arm_group_label>Aspiration thrombectomy</arm_group_label>
    <description>Patients with acute ischemic stroke of the anterior circulation whom the treating physician deemed eligible to be treated with SOFIA™/ SOFIA™ as a first line treatment technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sofia</intervention_name>
    <description>The SOFIA™/ SOFIA™ PLUS Catheter will be used in removal/aspiration of emboli and thrombi following the CE marked Instructions For Use. Enrollment into the study does not change the routine care at the site provided to the patient requiring mechanical thrombectomy treatment.</description>
    <arm_group_label>Aspiration thrombectomy</arm_group_label>
    <other_name>Microvention - SOFIA Catheter</other_name>
    <other_name>Microvention - SOFIA Plus Catheter</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are at least 18 years of age presenting with an acute ischemic event in the
        anterior cerebral circulation that can be treated within 6 hours from AIS symptom onset.
        Those eligible to be treated with SOFIA™/ SOFIA™ PLUS will be enrolled after having signed
        an informed consent form (or having one signed on his or her behalf by a legally authorized
        representative).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant is ≥ 18

          2. Demonstrated occlusion of the distal intracranial carotid artery, middle cerebral
             artery (M1 or M2) or anterior cerebral artery (A1 or A2) proven by CT and/or MRI

          3. NIHSS ≥ 2 and ≤ 30 at screening

          4. Start of the thrombectomy procedure within 6 hours of the onset of stroke symptoms

          5. Pre event mRS ≤1

          6. Patient or patient's legally authorized representative has received information about
             data collection and has signed and dated an Informed Consent Form

        Exclusion Criteria:

          1. Patient is more than 6 hours from symptom onset

          2. Rapidly improving neurologic examination

          3. Evidence of cerebral ischemia in the posterior circulation

          4. Severe unilateral or bilateral carotid artery stenosis requiring stent treatment

          5. Presence of an existing or pre-existing large territory infarction

          6. Absent femoral pulses

          7. Excessive vascular tortuosity that will likely result in unstable access

          8. Pregnancy; if a woman is of child-bearing potential a urine or serum beta HCG test is
             positive

          9. Known contrast product allergy

         10. Patient has a severe or fatal comorbidity that will likely prevent improvement or
             follow up or that will render the procedure unlikely to benefit the patient

         11. Evidence of intracranial hemorrhage (SAH, ICH, etc.)

        Imaging exclusion criteria:

          -  Significant mass effect with midline shift or intracranial tumor

          -  Baseline non-contrast CT or DWI MRI evidence of a moderate/large core defined as
             extensive early ischemic changes of Alberta Stroke Program Early CT score (ASPECTS)
             0-5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus A Möhlenbruch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Bonekamp, DVM</last_name>
    <phone>+4962215635710</phone>
    <email>susanne.bonekamp@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lukas Diebold</last_name>
    <phone>+4962215638346</phone>
    <email>lukas.diebold@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Trenkler, MD</last_name>
      <email>johannes.trenkler@kepleruniklinikum.at</email>
    </contact>
    <contact_backup>
      <last_name>Elke Bach</last_name>
      <email>Elke.Bach@kepleruniklinikum.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Salzburger Landeskliniken</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Killer-Oberpfalzer, MD</last_name>
      <email>m.killer@salk.at</email>
    </contact>
    <contact_backup>
      <last_name>Angela Jedlitschka</last_name>
      <email>a.jedlitschka@salk.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Le Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33404</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Barreau, MD</last_name>
      <email>xavier.barreau@chu-bordeaux.fr;</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>69037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Esstrade, MD</last_name>
      <email>laurentestrade@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nasreddine Nouri, MD</last_name>
      <email>nasri06@yahoo.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Cognard, MD</last_name>
      <email>cognard.c@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Christine Januel, MD</last_name>
      <email>januel.ac@chu-toulouse.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus A Möhlenbruch, MD</last_name>
      <email>markus.moehlenbruch@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Lukas Diebold</last_name>
      <email>lukas.diebold@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ansgar Berlis, MD</last_name>
      <email>ansgar.berlis@klinikum-augsburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Ilse Kummer</last_name>
      <email>Ilse.Kummer@klinikum-augsburg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Bohner, MD</last_name>
      <email>georg.bohner@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Annett Schreck</last_name>
      <email>annett.schreck@charite.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Knappschaftskrankenhaus Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Fischer, MD</last_name>
      <email>sebastian.fischer@kk-bochum.de</email>
    </contact>
    <contact_backup>
      <last_name>Werner Weber, MD</last_name>
      <email>werner.weber@kk-bochum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Reith, MD</last_name>
      <email>wolfgang.reith@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fritz Wodarg, MD</last_name>
      <email>fritz.wodarg@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Krieter, MA</last_name>
      <email>sabine.krieter@uksh.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Policlinico &quot;G. Martino&quot; di Messina</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pitrone, MD</last_name>
      <email>a.pitrone@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinoud Bokkers, MD</last_name>
      <email>r.p.h.bokkers@umcg.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Dr. Markus Alfred Möhlenbruch</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Thrombectomy</keyword>
  <keyword>Aspiration Thrombectomy</keyword>
  <keyword>Observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

